信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习

Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induce...

Descripción completa

Detalles Bibliográficos
Autores principales: CAI, Jingjing, YANG, Guangxia, ZHANG, Xuemei, LIU, Linlin, YAN, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600748/
https://www.ncbi.nlm.nih.gov/pubmed/37985158
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.32
_version_ 1785126052299800576
author CAI, Jingjing
YANG, Guangxia
ZHANG, Xuemei
LIU, Linlin
YAN, Mei
author_facet CAI, Jingjing
YANG, Guangxia
ZHANG, Xuemei
LIU, Linlin
YAN, Mei
author_sort CAI, Jingjing
collection PubMed
description Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment.
format Online
Article
Text
id pubmed-10600748
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-106007482023-10-27 信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习 CAI, Jingjing YANG, Guangxia ZHANG, Xuemei LIU, Linlin YAN, Mei Zhongguo Fei Ai Za Zhi Case Report Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment. Editorial board of Chinese Journal of Lung Cancer 2023-09-20 /pmc/articles/PMC10600748/ /pubmed/37985158 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.32 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Case Report
CAI, Jingjing
YANG, Guangxia
ZHANG, Xuemei
LIU, Linlin
YAN, Mei
信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
title 信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
title_full 信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
title_fullStr 信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
title_full_unstemmed 信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
title_short 信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
title_sort 信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600748/
https://www.ncbi.nlm.nih.gov/pubmed/37985158
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.32
work_keys_str_mv AT caijingjing xìndílìdānkàngzhìfèiáihuànzhěmiǎnyìxìngxuèxiǎobǎnjiǎnshǎo1lìbìngwénxiànfùxí
AT yangguangxia xìndílìdānkàngzhìfèiáihuànzhěmiǎnyìxìngxuèxiǎobǎnjiǎnshǎo1lìbìngwénxiànfùxí
AT zhangxuemei xìndílìdānkàngzhìfèiáihuànzhěmiǎnyìxìngxuèxiǎobǎnjiǎnshǎo1lìbìngwénxiànfùxí
AT liulinlin xìndílìdānkàngzhìfèiáihuànzhěmiǎnyìxìngxuèxiǎobǎnjiǎnshǎo1lìbìngwénxiànfùxí
AT yanmei xìndílìdānkàngzhìfèiáihuànzhěmiǎnyìxìngxuèxiǎobǎnjiǎnshǎo1lìbìngwénxiànfùxí

Ejemplares similares